# Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

> **NCT03045861** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 33 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** GSK2838232
- **DRUG:** Cobicistat

## Key facts

- **NCT ID:** NCT03045861
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-17
- **Primary completion:** 2018-04-23
- **Final completion:** 2018-04-23
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03045861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03045861, "Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03045861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*